Zorn v. Linton

On March 23, 2026, the U.S. District Court for the Northern District of California heard opening arguments in Zorn v. Linton, a landmark wrongful death suit. Martha Zorn, aged 52, died from a severe immune reaction following an experimental CRISPR-based therapy for a rare liver disorder. Her husband, Jonathan Zorn, sued David Linton, the lead researcher at BioGenX Corporation, alleging that Linton grossly deviated from the approved clinical protocol and failed to disclose a known risk of off-target genomic edits. The plaintiff contends that Linton rushed the trial to secure venture funding, directly causing a fatal cytokine storm and massive organ failure. The defense maintains the death was an unforeseeable tragedy and that all consent forms adequately explained the risks.

As of the case filing and preliminary hearings in early 2026, the court has denied the defendant's motion to dismiss, allowing the lawsuit to proceed into the discovery phase. A jury trial is anticipated in late 2026.

The central dispute is whether David Linton and BioGenX committed gross negligence by intentionally ignoring early safety signals and inadequately informing Martha Zorn about the specific risk of lethal immune hyperactivation linked to the therapy's delivery vector.

The case has sent shockwaves through the biotechnology industry, causing venture capital investment in early-stage gene therapy to plummet by 30%. It has intensified public calls for stricter FDA oversight of CRISPR human trials and sparked a national debate over how to balance medical innovation with patient safety when researchers face significant financial conflicts of interest.